Information about opioids
In July 2017, ExamOne announced it offers an opens in a new windowexpanded opioid panel for life insurers. For the last three decades, ExamOne has offered two main options (see table below) for full urine drug screens to help insurers identify risk in the insurance population.
These screens were developed in the 1980s and are recommended by the Substance Abuse and Mental Health Services Administration (SAMHSA, formerly the National Institute on Drug Abuse, NIDA) for the testing of certain federal employees, as well as specified Department of Transportation (DOT) regulated occupations.
The expanded panel detects semi-synthetic opioid use and includes the following drugs: codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, fentanyl and heroin. As with all drug testing, positive screens are confirmed with gas chromatography/mass spectrometry (gc/ms).
Learn more about the risks and impacts of opioid abuse in America
More laboratory resources
We are committed to providing you with the resources you need to underwrite with full confidence. This section highlights specific laboratory tests and why you should include them in your standard insurance testing panel.